论文部分内容阅读
目的观察依达拉奉联合奥扎格雷钠治疗急性脑梗死的疗效。方法98例急性脑梗死患者随机分为治疗组与对照组,在常规治疗的基础上,治疗组联合应用依达拉奉和奥扎格雷钠,对照组单独使用奥扎格雷钠,疗程14d,以美国国立卫生研究院卒中量表(NIHSS)和Barthel指数(BI)为指标,评价疗效。结果治疗14d后患者临床神经功能缺损程度改善治疗组优于对照组(P<0.05),3个月时治疗组日常生活活动能力优于对照组。结论依达拉奉联合奥扎格雷钠治疗急性脑梗死比单用奥扎格雷钠疗效好,无明显副反应。
Objective To observe the efficacy of edaravone and ozagrel sodium in the treatment of acute cerebral infarction. Methods A total of 98 patients with acute cerebral infarction were randomly divided into treatment group and control group. On the basis of conventional treatment, edaravone and ozagrel sodium were used in the treatment group, and sodium ozagrel alone in the control group for 14 days. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used as indicators to evaluate the efficacy. Results After 14 days of treatment, the clinical neurological deficit improvement was better in the treatment group than in the control group (P <0.05). At 3 months, the activities of daily living in the treatment group were better than those in the control group. Conclusion Edaravone combined with ozagrel sodium in the treatment of acute cerebral infarction than ozagrel sodium alone is effective and has no obvious side effects.